LCZ696単剤療法でコントロール不良なグレード1および2の高血圧患者におけるLCZ696/アムロジピンの有効性と安全性の試験

基本情報

NCT ID

NCT06236061

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

718

治験依頼者名

Novartis

概要

This CLAZ696B11302 study is composed of two parts; the Core part including double-blind period, and the open-label extension (OLE) part which is an open-label extension of the Core part. The purpose of the Core part is to demonstrate that LCZ696 (LCZ) when used in combination with amlodipine (AML), denoted as LCZ/AML, will provide greater blood pressure lowering benefit compared to LCZ monotherapy in patients with grade 1 and 2 hypertension not adequately controlled with LCZ monotherapy. The purpose of the OLE part is to assess the long-term safety, tolerability and efficacy of the treatment with LCZ/AML.

対象疾患

介入

依頼者（Sponsor）